Charles River jumps on guidance hike as biotech demand rebounds
+11.36% to $260.72 from $234.12
What moved CRL
- Q2 revenue of $1.00 billion beat the $979.9 million estimate; adjusted EPS of $3.02 beat the $2.73 estimate.
- The company raised FY2026 adjusted EPS guidance to $11.15-$11.45, from a prior $10.80-$11.30.
- FY2026 revenue forecast was raised to $3.879 billion-$3.920 billion, from a prior $3.794 billion-$3.854 billion.
- The Discovery and Safety Assessment segment booked its highest net book-to-bill ratio in nearly four years, with demand improving across large pharma and small-cap biotech clients.
Sources: StockStory · Benzinga